|
Healthcare Sector Review: Bristol-Myers Squibb Warning, NuVasive's Injunction …
Wall St. Cheat Sheet XenoPort and GSK entered into the agreement to develop and commercialize Horizant tablets, which was approved in the United States in April 2011 for the treatment of moderate-to-severe primary restless legs syndrome in adults. |
View full post on restless leg syndrome – Google News
